Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by johnny007on Jun 02, 2021 7:33pm
132 Views
Post# 33316061

RE:RE:Milestones from Q1 conference call for Q2 and rest of year

RE:RE:Milestones from Q1 conference call for Q2 and rest of yearwithin 2Q2021 (now)
  • Ramping up our marketing to target patients and families within our US Care Oncology network.
  • Planning to launch broad-based social media marketing, with the launch of direct-to-consumer campaigns, for AVRT and Aristotle in key markets.
  • Plan to close on the Care Oncology acquisition.
until end of 2021
  • Planning a marketing campaign targeting B2B partners, including channel partners, and self-insured, and re-insureds.
  • Targeting to launch employer pilot programs with innovators and early adopter employer groups.
  • Planning multi-channel marketing with national B2B and B2C campaigns
Ok Lith .. this answers a few topics of my 'angry list'.

Would be great if Tripp could bring much more light into the acquisition and how this shall play out, i.e. giving numbers and concrete examples how to do it (_color_).
At least it is the nature of my peers and myself to know a little bit more from the horses mouth, instead of pulling teeth all on our own :-)

I checked the balance sheets last quarters, result:
  Only the paper losses and paper liabilities exist (warrants),
  otherwise non-GAAP all green and positive.
  Great!

Then I also checked the last weeks and months of trades and real short interest.
From 7M shares short, we are down to sort of zero today.
Besides the stock price massacre .. also looks great.

Yes, SHIFT/ has a good reputation and they knwo how to market products and services.
https://www.shiftcomm.com/work/category/healthcare/

The more meat will be added to the now naked bones of this stock,
the better it shall recover - OK.
Becoming mildly optimistic.

Yes, I remember I heard all these points in the CC,
but to be honest - the stock selling made me and others surely def on the fine details.
https://seekingalpha.com/article/4429384-stagezero-life-sciences-ltd-gnwsf-ceo-james-howard-tripp-on-q1-2021-results-earnings-call

And Tripp & Company: Please add more color to all of your goals.
In the end, you pick up all the original targets within 2021, which is great if working out.
Hence send a love letter to Clarus as well, I am sure - the B2B and B2B direct and [re-]insured were intended for them as well.

Everybody have a good one!
<< Previous
Bullboard Posts
Next >>